Reduced pressure wound dressing having a wound contact surface with columnar protrusions

Information

  • Patent Grant
  • 9107989
  • Patent Number
    9,107,989
  • Date Filed
    Friday, November 4, 2011
    13 years ago
  • Date Issued
    Tuesday, August 18, 2015
    9 years ago
Abstract
A reduced pressure treatment system includes a distribution manifold having a backing substrate with a first side and a second side and a plurality of protrusions positioned on the first side of the backing substrate. Each of the protrusions includes a substantially circular cross-sectional shape and has a diameter of between about 0.1 and 2.0 millimeters, the backing substrate having a plurality of apertures formed therein to allow fluid communication between the first side and the second side opposite the first side. A reduced pressure source is fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to a tissue site.
Description
BACKGROUND

1. Field of the Invention


The present invention relates generally to tissue treatment systems and in particular to distribution manifolds for wound treatment.


2. Description of Related Art


Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including faster healing and increased formulation of granulation tissue. Typically, reduced pressure is applied to tissue through a porous pad or other manifolding device. The porous pad contains cells or pores that are capable of distributing reduced pressure to the tissue and channeling fluids that are drawn from the tissue. The porous pad often is incorporated into a dressing having other components that facilitate treatment.


Distribution manifolds for delivering reduced pressure treatment are also commonly referred to as reduced pressure dressings, or in the case of treatment of a wound, wound dressings. Such dressings are characterized by structural features that allow fluid flow through the material. For example, one material that is often used as a wound dressing is reticulated, open-cell polyurethane foam. The foam includes a plurality of interconnected pores that allow fluid flow throughout the foam. When a reduced pressure is applied to one area of the foam, this reduced pressure is quickly distributed to other areas of the foam and is easily transmitted to tissues adjacent the foam. One problem with open-cell foams and similar materials is tissue in-growth, which prevents easy removal of the foam following treatment. For open cells foams with pore sizes on the order of 100-1000 microns, in-growth of tissue may occur relatively quickly. As the new tissue enters the pores or cells of the foam, the foam acts as a lattice, and tissue grows within the pores and around the walls that form the perimeter of the pores. This effectively attaches the foam to the tissue site, and the foam must be forcibly removed by tearing the new tissue and breaking any bonds that have formed between the tissue and the foam. Not only is this detrimental to the healing process, but the tearing of this tissue may cause discomfort to the patient.


One way to circumvent the problem of tissue in-growth is to increase the frequency of dressing changes. If new dressings are applied with increased frequency, there is less tissue in-growth, and thus less disruption of new tissue upon removing the old dressing. One downside to increased dressing changes is the increased costs associated with materials (i.e. new dressings) and labor. Changing a dressing is labor intensive and diverts the attention of medical personnel from other important tasks. Increased dressing changes also result in more aggravation to patients and their wounds.


SUMMARY

The problems presented by existing reduced pressure treatment systems are solved by the systems and methods of the illustrative embodiments described herein. In one embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of protrusions positioned on a first side of the backing substrate with each of the protrusions having substantially circular cross-sectional shape and having a diameter of between about 0.1 and 2.0 millimeters. The backing substrate has a plurality of apertures formed therein to allow fluid communication between the first side and a second side opposite the first side. A reduced pressure source fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to a tissue site.


In another embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of protrusions positioned on a first side of the backing substrate, each of the protrusions having a substantially polygonal cross-sectional shape and having a width of between about 0.1 and 2.0 millimeters. The backing substrate has a plurality of apertures formed therein to allow fluid communication between the first side and a second side opposite the first side. A reduced pressure source fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to a tissue site.


In another embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of columnar voids positioned on a first side of the backing substrate, each of the columnar voids having substantially polygonal cross-sectional shape and having a width of between about 0.1 and 2.0 millimeters.


In another embodiment, a reduced pressure treatment system is provided and includes a distribution manifold including a backing substrate and a plurality of protrusions positioned on a first side of the backing substrate, each of the protrusions having substantially circular cross-sectional shape and tapering inward from the base at which the protrusions meet the backing substrate. The backing substrate has a plurality of apertures formed therein to allow fluid communication between the first side and a second side opposite the first side. A reduced pressure source is fluidly connected to the apertures of the backing substrate to deliver the reduced pressure through the apertures, between the protrusions, and to a tissue site.


Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates a reduced pressure treatment system 11 according to an embodiment of the present invention.



FIG. 2 illustrates the distribution manifold according to an embodiment of the present invention.



FIG. 3 illustrates the shape of the protrusions of the distribution manifold according to an embodiment of the present invention.



FIG. 4 illustrates a plurality of columnar voids of a distribution manifold according to an embodiment of the present invention.



FIG. 5 illustrates a plurality of columnar voids of a distribution manifold according to an embodiment of the present invention.



FIG. 6 illustrates a backing substrate with circular protrusions according to an embodiment of the present invention.



FIG. 7 represents an illustrated reproduction of a photograph of a distribution manifold taken through a microscope according to an embodiment of the present invention.



FIG. 8 represents an illustrated reproduction of a photograph of an exemplar distribution manifold having a plurality of columnar voids disposed in a backing substrate according to an embodiment of the present invention.





DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In the following detailed description of the illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.


The several embodiments of the present invention described herein are provided to assist in the healing of wounds and generation of new tissue. Reduced pressure therapy is administered to patients with a reduced pressure delivery system. This form of advanced wound healing therapy can be readily integrated into a clinician's wound healing procedures. The therapy optimizes patient care and decreases costs associated with treatment of patients having traumatic and chronic wounds. With the innovative embodiments of the reduced pressure delivery system described herein, reduced pressure therapy can be administered either in the hospital, in community settings such as assisted living complexes and convalescence homes, or in the home.


Reduced pressure delivery to a wound or tissue site promotes wound healing and/or tissue growth by removing infectious materials and other fluids from the wound or tissue site. Reduced pressure treatment further promotes tissue growth by imposing forces on the tissue, thereby causing micro-deformation of the tissue, which is believed to contribute to the development of granulation tissue at the tissue site. The forces imposed on the tissue site by the delivery of reduced pressure further encourage improved blood flow to the tissue site, which further assists in the growth of new tissue.


Referring to FIG. 1, a reduced pressure treatment system 11 according to an embodiment of the present invention includes a reduced pressure dressing, or distribution manifold 15 fluidly connected to a reduced pressure conduit 19. The reduced pressure conduit 19 is fluidly connected to a reduced pressure source 23 such as a vacuum pump or another source of suction. The distribution manifold 15 is placed against a tissue site 31 of a patient and is used to distribute a reduced pressure provided by the reduced pressure source 23. Typically, reduced pressure is maintained at the tissue site by placing an impermeable or semi-permeable cover 25 over the distribution manifold 15 and the tissue site 31. The reduced pressure also serves to draw wound exudates and other fluids from the tissue site 31. A canister 27 may be fluidly connected to the reduced pressure conduit 19 and disposed between the wound dressing 15 and the reduced pressure source 23 to collect the fluids drawn from the tissue site 31. A distribution adapter 35 may be connected to the reduced pressure conduit 19 and positioned on the distribution manifold 15 to aid in distributing the reduced pressure to the distribution manifold 15.


Referring to FIGS. 2 and 3, the distribution manifold 15 is particularly well suited to promote tissue growth at the tissue site 31 yet prevent in-growth of new tissue into the distribution manifold 15. The distribution manifold 15 includes a backing substrate 41 with a tissue contact surface 43. The tissue contact surface 43 preferably includes a plurality of projections, or protrusions 51 that extend from the backing substrate 41. As more specifically shown in FIG. 3, the shape of the protrusions 51 may be substantially cylindrical in shape. Alternatively, the cross-sectional shape of the protrusions 51 may be square, rectangular, triangular, polygonal, elliptical, or any other shape. The protrusions 51 may be tapered or of uniform cross-sectional area throughout.


Referring more specifically to FIG. 3, the height, H, of the protrusions 51 is preferably between about 0.1 and 5.0 millimeters, and more preferably about 2 millimeters. The width, W, of each protrusion is between about 0.1 and 2.0 millimeters, and more preferably about 0.25 to 0.5 millimeters. The width of the protrusions 51 illustrated in FIG. 3 equals that of the diameter since the cross-sectional shape of each protrusion 51 is circular. If the protrusions 51 are square in cross-sectional shape, the width of the protrusions 51 are an edge length of the square. For other cross-sectional shapes, the width is the average of the longest lateral distance through the centroid, C, of the cross section and the shortest lateral distance through the centroid of the cross section. The lateral, center-to-center spacing, E, between each protrusion 51 is preferably between about 0.1 and 1.0 millimeters, and more preferably about 0.5 millimeters. The spacing of the protrusions 51 create distribution channels 61 through which reduced pressure may be delivered to the tissue site 31 and exudates withdrawn from the tissue site 31. It is generally preferred that the height of the protrusions 51 be greater than the width of the protrusions 51. More specifically, the ratio of height to width, H:W, should be greater than about 1:1, and more preferably greater than about 2:1.


The shape, sizing, and spacing of the protrusions 51 may vary depending upon the particular tissue site 31 being treated, the type of material from which the protrusions 51 and backing substrate 41 are made, and the amount of reduced pressure being applied to the tissue site 15. For example, for tissue sites that are highly exudating, it may be advantageous to position the protrusions farther apart to maintain adequate distribution channels 61 between the protrusions 51. In one embodiment of the present invention, the shape, sizing and spacing of the protrusions 51 is uniform for a particular distribution manifold 15. In other embodiments, the shape, sizing, and spacing of the protrusions 51 may vary. For example, protrusions 51 having different cross-sectional shapes may be disposed on the backing substrate 41. Similarly, the sizing and spacing of the protrusions 51 may vary to supply selected portions of the tissue site 31 with more or less reduced pressure.


The presence and sizing of the protrusions 51 allow the protrusions 51 to distribute reduced pressure to the tissue site 31, but prevent new tissue that grows at the tissue site 31 from attaching to the protrusions 51 of the distribution manifold 15. By eliminating the pores or cells that are typically used to deliver reduced pressure to a tissue site, new tissue is not able to wrap around the walls that form the pores or cells. While new tissue growth will grow into the field of protrusions 51 and may even wrap around some of the protrusions 51, the new tissue is not capable of securing itself to the protrusions 51 since the base of each protrusion is anchored to the backing substrate 41.


In addition to distributing reduced pressure to the tissue site 31, the distribution manifold 15 also serves to impart stresses and strains to the tissue site 31 similar to those seen with cellular foam that traditionally has been used in reduced pressure systems. Other materials sometimes used in reduced pressure systems as distribution manifolds, such as gauze, do not have this effect on tissue. The stresses and strains created by the distribution manifold 15 are believed to cause micro-deformation of existing tissue and plays a significant role in the generation of new tissue at the tissue site. The amount of stress and strain imparted to a tissue site is determined by the amount of reduced pressure supplied to the tissue site and the surface morphology of the manifold that contacts the tissue site. As reduced pressure is applied, portions of the tissue site are pulled against the distribution manifold 15, and more particularly against the protrusions 51, which results in the development of stresses and strains within the tissue. The sizing of the protrusions 51 on a scale similar to that of the pores of the cellular foam is believed to be one reason for the development of stresses and strains that are similar to those seen with use of the foam.


In one embodiment, the backing substrate 41 is formed from the same material as the protrusions 51. Preferably, that material is silicone or another medical grade material that is relatively impermeable to fluid flow. Alternatively, the material may be a semi-permeable material that allows select fluids or amounts of fluids to pass. The backing substrate 41 may include a plurality of apertures 71 that allow distribution from a surface of backing substrate 41 opposite the protrusions 51 to the tissue contact surface 43 from which the protrusions 51 extend. Since the presence of the apertures 71 could have the same effect on tissue in-growth as that of pores, it is important that the backing substrate 41 and protrusions 51 be removed from the tissue site 31 prior to any new tissue advancing into the apertures 71. In practice, this may be accomplished by knowing the approximate rate of tissue growth, the height of the protrusions 51, and determining the amount of time likely required for new tissue growth to reach the apertures 71.


While the distribution manifold 15 has primarily been described as including backing substrate 41 and plurality of protrusions 51, the distribution manifold 15 may further include cellular foam or another material that is positioned adjacent to or attached to the surface of the backing substrate 41 opposite the protrusions 51. The use of a cellular foam or other material increases the ability of the reduced pressure conduit 19 or the distribution adapter 35 to deliver and distribute reduced pressure to the backing substrate 41. The protrusions 51 and backing substrate 41 serve as a barrier to new tissue growth entering pores of the cellular foam or other material.


Referring to FIGS. 4 and 5, a distribution manifold 115 according to another embodiment of the present invention is illustrated. Instead of a plurality of protrusions such as those of distribution manifold 15, distribution manifold 115 includes a plurality of columnar voids 151 formed or otherwise positioned within a backing substrate 141. The term columnar is not meant to imply any particular cross-sectional shape, since the shape of the voids may be any shape as described previously with reference to protrusions 51. Rather, the term columnar refers to the voids generally being greater in length than in width. The voids 151 themselves create a plurality of distribution channels 161 that may be joined by a main channel at an end of the distribution channels 161 opposite that of a tissue site. Alternatively, the distribution channels 161 may simply be apertures that pass completely through the backing substrate 141.


The shape and size of the voids 151 may be similar to that of the protrusions 51 of manifold 15. As previously described, a cellular foam, distribution adapter, or other manifolding device may be placed in fluid communication with the distribution channels 161 to deliver reduced pressure to the tissue site.


Exemplary Distribution Manifold Having Protrusions


Referring to FIGS. 6 and 7, one particular distribution manifold 215 that has been tested and that has demonstrated growth induction rates similar to those of cellular foam utilizes a two inch diameter backing substrate 241. The backing substrate includes a plurality of protrusions 251 that are generally circular in cross-sectional shape and tapered inward from the base at which the protrusions meet the backing substrate 241. A plurality of apertures 271 are provided in the backing substrate 241 to allow fluid communication with distribution channels 261 between the protrusions 251. The apertures 271 are disposed in rows and columns that are positioned between the rows and columns of the protrusions 251. The positioning of the apertures 271 in this pattern results in one aperture 271 being centered between every four adjacent protrusions 251 that are arranged in a square pattern (see FIG. 6).


The sizing of the protrusions 215 is such that on the two inch diameter backing substrate 241, approximately 7500 protrusions are present. The width of each protrusion at the base is about 0.5 mm, the height of each protrusion is about 1.5 mm, and the lateral center-to center spacing between the protrusions is about 0.75 mm. The ratio of height to width of the protrusions is about 3:1, and the ratio of the spacing to width is about 1.5:1. The tapering of each protrusion 51 is about a five degree draft angle from the longitudinal axis of the protrusions 51 to aid in molding the distribution manifold 215.


Distribution manifold 215 was sized based on an expected rate of tissue growth and the desired period of use between changes of the distribution manifold 215. For reduced pressures of about 125 mm Hg, one to two millimeters of tissue growth may be expected over a 48 hour period. Since it is desired to change the distribution manifold 215 every 48 hours, a protrusion height of about 1.5 mm allows the majority of the spacing between the protrusions 251 to fill with new tissue growth between dressing changes, but prevents the tissue from attaching to the distribution manifold 251.


Referring more specifically to FIG. 7, an illustrated reproduction of a photograph of the distribution manifold 215 taken through a microscope is provided. The photograph illustrates a top view of the distribution manifold 215 showing the protrusions 251 extending from the backing substrate 241. Also illustrated are apertures 271 disposed between the protrusions 251.


Exemplary Distribution Manifold Having Voids


Referring to FIG. 8, an illustrated reproduction of a photograph of an exemplar distribution manifold 315 having a plurality of columnar voids 351 disposed in a backing substrate 341 is provided. The backing substrate 341 is about 1.5 mm thick, and the width (diameter) of each void 351 is about 0.35 mm. Since the voids 351 extend through the backing substrate 341, the height of each void 351 is about 1.5 mm. The lateral center-to-center spacing between the voids 351 is about 0.75 mm. The ratio of height to width of the voids is about 4.3:1, and the ratio of the spacing to width is about 2.1:1.


It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.

Claims
  • 1. A reduced pressure treatment system for delivering a reduced pressure to a tissue site comprising: a distribution manifold including a backing substrate having a first side adapted to face a tissue site, a second side opposite the first side, and a plurality of protrusions extending from the first side of the backing substrate, wherein the plurality of protrusions have a substantially circular cross-sectional shape having a width between about 0.1 and 2.0 millimeters and a height greater than the width, and wherein the backing substrate has a plurality of apertures formed between the first side and the second side to allow fluid communication between the first side and the second side; anda reduced pressure source adapted to be fluidly connected to the apertures on the second side and configured to deliver reduced pressure through the apertures to the first side between the protrusions and to the tissue site;whereby the protrusions maintain a specific height to width ratio that prevents new tissue growth from attaching to the distribution manifold.
  • 2. The reduced pressure treatment system of claim 1, wherein a lateral center-to-center spacing of the protrusions is between about 0.1 and 0.5 millimeters.
  • 3. The reduced pressure treatment system of claim 1, wherein a ratio of the height to diameter of the protrusions is 2:1.
  • 4. The reduced pressure treatment system of claim 1, wherein the protrusions are made from medical grade silicone.
  • 5. A reduced pressure treatment system for delivering a reduced pressure to a tissue site comprising: a distribution manifold including a backing substrate having a first side adapted to face a tissue site, a second side opposite the first side, and a plurality of protrusions extending from the first side of the backing substrate, wherein the plurality of protrusions have a substantially polygonal cross-sectional shape having a width between about 0.1 and 2.0 millimeters and a height greater than the width, and wherein the backing substrate has a plurality of apertures formed between the first side and the second side to allow fluid communication between the first side and the second side; anda reduced pressure source adapted to be fluidly connected to the apertures on the second side and configured to deliver reduced pressure through the apertures to the first side between the protrusions and to the tissue site;whereby the protrusions maintain a specific height to width ratio that prevents new tissue growth from attaching to the distribution manifold.
  • 6. The reduced pressure treatment system of claim 5, wherein a lateral center-to-center spacing of the protrusions is between about 0.1 and 0.5 millimeters.
  • 7. The reduced pressure treatment system of claim 6, wherein a ratio of the height of the protrusions to the width of the protrusions is 2:1.
  • 8. The reduced pressure treatment system of claim 5, wherein the protrusions are made from medical grade silicone.
  • 9. A reduced pressure treatment system for delivering a reduced pressure to a tissue site comprising: a distribution manifold including a backing substrate having a first side adapted to face a tissue site, a second side opposite the first side, and a plurality of columnar voids extending from the first side of the backing substrate, wherein the plurality of columnar voids have a substantially polygonal cross-sectional shape having a width between about 0.1 and 2.0 millimeters and a height greater than the width, and wherein the backing substrate has a plurality of apertures formed between the first side and the second side to allow fluid communication between the first side and the second side; anda reduced pressure source adapted to be fluidly connected to the apertures on the second side and configured to deliver reduced pressure through the apertures to the first side between the columnar voids and to the tissue site;whereby the columnar voids maintain a specific height to width ratio that prevents new tissue growth from attaching to the distribution manifold.
  • 10. The reduced pressure treatment system of claim 9, wherein a height of the columnar voids is about 1.5 mm.
  • 11. The reduced pressure treatment system of claim 9, wherein the backing substrate is about 1.5 mm thick.
  • 12. The reduced pressure treatment system of claim 9, wherein the columnar voids completely pass through the backing substrate.
  • 13. The reduced pressure treatment system of claim 9, wherein a lateral center-to-center spacing between the plurality of columnar voids is about 0.75 mm.
  • 14. The reduced pressure treatment system of claim 9 wherein: the columnar voids create a plurality of distribution channels that are joined to a main channel at an end of the distribution channels; anda reduced pressure source is fluidly connected to the distribution channels of the backing substrate to deliver the reduced pressure to the tissue site.
  • 15. The reduced pressure treatment system of claim 14, further comprising a cellular foam positioned adjacent to the plurality of distribution channels.
  • 16. The reduced pressure treatment system of claim 9, wherein the plurality of columnar voids are square, rectangular, triangular, polygonal, or elliptical shaped.
  • 17. The reduced pressure treatment system of claim 9, wherein the plurality of columnar voids are tapered.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 12/118,524, filed May 9, 2008 now U.S. Pat. No. 8,057,447, which claims the benefit of U.S. Provisional Application No. 60/928,644, filed May 10, 2007, both of which are hereby incorporated by reference.

US Referenced Citations (168)
Number Name Date Kind
1355846 Rannells Oct 1920 A
2305289 Coburg Dec 1942 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3026874 Stevens Mar 1962 A
3066672 Crosby, Jr. et al. Dec 1962 A
3089492 Owens May 1963 A
3142298 Koski et al. Jul 1964 A
3367332 Groves Feb 1968 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
3992162 Gewiss Nov 1976 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez, Jr. Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4250882 Adair Feb 1981 A
4256109 Nichols Mar 1981 A
4261360 Perez Apr 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4342745 Mirkovitch Aug 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4444545 Sanders et al. Apr 1984 A
4465485 Kashmer et al. Aug 1984 A
4468219 George et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vaillancourt Jun 1985 A
4533352 Van Beek et al. Aug 1985 A
4534356 Papadakis Aug 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielsen Aug 1986 A
4614183 McCracken et al. Sep 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4795435 Steer et al. Jan 1989 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4919654 Kalt et al. Apr 1990 A
4930997 Bennett Jun 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4979944 Luzsicza Dec 1990 A
4985019 Michelson Jan 1991 A
5013300 Williams May 1991 A
5034006 Hosoda et al. Jul 1991 A
5037397 Kalt et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5195977 Pollitt Mar 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5260066 Wood et al. Nov 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5449347 Preen et al. Sep 1995 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5607388 Ewall Mar 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5735833 Olson Apr 1998 A
5762640 Kajiwara et al. Jun 1998 A
5776119 Bilbo et al. Jul 1998 A
5827246 Bowen Oct 1998 A
5902260 Gilman et al. May 1999 A
5941859 Lerman Aug 1999 A
6051747 Lindqvist et al. Apr 2000 A
6071267 Zamierowski Jun 2000 A
6080243 Insley et al. Jun 2000 A
6135116 Vogel et al. Oct 2000 A
6142982 Hunt Nov 2000 A
6241747 Ruff Jun 2001 B1
6287316 Agarwal et al. Sep 2001 B1
6345623 Heaton et al. Feb 2002 B1
6458109 Henley et al. Oct 2002 B1
6471982 Lydon et al. Oct 2002 B1
6482491 Samuelsen et al. Nov 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6553998 Heaton et al. Apr 2003 B2
6566575 Stickels et al. May 2003 B1
6572594 Satterfield et al. Jun 2003 B2
6660484 Charych et al. Dec 2003 B2
6682506 Navarro Jan 2004 B1
6695823 Lina et al. Feb 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6814079 Heaton et al. Nov 2004 B2
7070584 Johnson et al. Jul 2006 B2
7117869 Heaton et al. Oct 2006 B2
7195624 Lockwood et al. Mar 2007 B2
7273054 Heaton et al. Sep 2007 B2
7276051 Henley et al. Oct 2007 B1
7316672 Hunt Jan 2008 B1
7344512 Yamazaki et al. Mar 2008 B2
7381859 Hunt et al. Jun 2008 B2
7396339 Britto et al. Jul 2008 B2
7651484 Heaton et al. Jan 2010 B2
7670323 Hunt et al. Mar 2010 B2
7846141 Weston Dec 2010 B2
7867206 Lockwood et al. Jan 2011 B2
7886746 Heaton et al. Feb 2011 B2
8057447 Olson et al. Nov 2011 B2
20020065494 Lockwood et al. May 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20020161346 Lockwood et al. Oct 2002 A1
20030108587 Orgill et al. Jun 2003 A1
20040073151 Weston Apr 2004 A1
20040127836 Sigurjonsson et al. Jul 2004 A1
20050004534 Lockwood Jan 2005 A1
20050261642 Weston Nov 2005 A1
20050283105 Heaton et al. Dec 2005 A1
20070118096 Smith et al. May 2007 A1
20080275409 Kane et al. Nov 2008 A1
Foreign Referenced Citations (51)
Number Date Country
550575 Aug 1982 AU
745271 Apr 1999 AU
755496 Feb 2002 AU
2005436 Jun 1990 CA
26 40 413 Mar 1978 DE
3907007 Sep 1990 DE
43 06 478 Sep 1994 DE
295 04 378 Oct 1995 DE
0080179 Nov 1982 EP
0100148 Feb 1984 EP
0117632 Sep 1984 EP
0161865 Nov 1985 EP
0300621 Jan 1989 EP
0358302 Mar 1990 EP
0619105 Apr 1994 EP
018967 Aug 2004 EP
692578 Jun 1953 GB
1579860 Apr 1976 GB
2125296 Mar 1984 GB
2195255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2227035 Oct 1994 GB
2 333 965 Aug 1999 GB
2 329 127 Aug 2000 GB
56-500360 Mar 1981 JP
A 59-141943 Aug 1984 JP
4129536 Apr 1992 JP
2005312343 Oct 2005 JP
2006325532 Jul 2006 JP
2242956 Dec 2004 RU
71559 Apr 2002 SG
WO 8002182 Oct 1980 WO
WO 8704626 Aug 1987 WO
WO 90010424 Sep 1990 WO
WO 9011795 Oct 1990 WO
WO 9309727 May 1993 WO
WO9417765 Aug 1994 WO
WO 9420041 Sep 1994 WO
WO 9517912 Jul 1995 WO
WO 9605873 Feb 1996 WO
WO 9718007 May 1997 WO
WO 9913793 Mar 1999 WO
WO 2001034223 May 2001 WO
WO 2001037922 May 2001 WO
WO 0185248 Nov 2001 WO
WO 0189431 Nov 2001 WO
WO 03045492 Jun 2003 WO
WO 03057070 Jul 2003 WO
WO2004018020 Mar 2004 WO
Non-Patent Literature Citations (96)
Entry
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of the Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986);pp. 94-96 (certified translation).
Louis C. Argenta, MD and Michael J. Morykwas, PhD; “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience”; Annals of Plastic Surgery, vol. 38, No. 6, Jun. 1997; pp. 563-576.
Susan Mendez-Eastmen, RN; “When Wounds Won't Heal” RN Jan. 1998, vol. 61(1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24.
James H. Blackburn, II, MD, et al; “Negative-Pressure Dressings as a Bolster for Skin Grafts”; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457.
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK.
S.E. Greer, et al “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487.
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639.
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80.
International Search Report for PCT International Application PCT/GB95/01983; Nov. 23, 1995.
PCT International Search Report for PCT International Application PCT/GB98/02713; Jan. 8, 1999.
PCT Written Opinion; PCT International Application PCT/GB98/02713; Jun. 8, 1999.
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; Jan. 15, 1998 & Apr. 29, 1997.
PCT Written Opinion, PCT International Application PCT/GB96/02802; Sep. 3, 1997.
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5.
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof.
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof.
Yusupov. Yu. N., et al; “Active Wound Drainage”, Vestnik Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof.
Davydov, Yu. A,, et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirurgi, Oct. 1988, pp. 48-52, and 8 page English translation thereof.
Davydov, Yu. A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof.
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63.
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24.
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2.
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534.
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81.
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213.
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221.
Svedman, P. et al.: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246.
G. {hacek over (Z)}ivadinović, V. ukić, {hacek over (Z)}. Maksimović, . Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation).
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585.
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967 (certified translation).
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370.
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513.
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I).
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax, ” Journal of the American Medical Association 64 (1915), pp. 1548-1549.
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909 , pp. 17-25, 44-64, 90-96, 167-170, and 210-211.
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”).
V.A. Kuznetsov & N. A. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”).
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”).
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians (Jul. 2007).
Notice of Opposition date mailed Apr. 28, 2010 in European Patent No. 1772160.
International Search Report and Written Opinion date mailed Aug. 4, 2008 for PCT/US2008/063305.
Notice of Opposition date mailed Oct. 13, 2010 to European Patent No. 1637088.
Teder, et al., “Continuous Wound Irrigation in the Pig” Journal of Investigative Surgery, vol. 3, pp. 399-407; 1990 (opp-459).
Response filed Feb. 14, 2011 to Smith and Nephew's Opposition for EP Patent No. 1637088.
Kane et al “Controlled Induction of Distributed Microdeformation in Wounded Tissue via a Microchamber Array Dressing”, pp. 333-340; Journal of Biomedical Materials Research; Nov. 2010, vol. 95A, Issue 2.
Quayle Office Action dated Nov. 16, 2001 for U.S. Appl. No. 09/613,497.
Response filed Mar. 19, 2004 for U.S. Appl. No. 09/613,497.
Non-Final Office Action dated Jul. 13, 2004 for U.S. Appl. No. 09/613,497.
Response filed Jan. 12, 2005 for U.S. Appl. No. 09/613,497.
Non-Final Office Action dated Feb. 7, 2006 for U.S. Appl. No. 09/613,497.
Response filed Jul. 8, 2006 for U.S. Appl. No. 09/613,497.
Notice of Non-Compliant dated Jul. 14, 2006 for U.S. Appl. No. 09/613,497.
Response filed Aug. 10, 2006 for U.S. Appl. No. 09/613,497.
Notice of Allowance and Fee(s) Due dated Oct. 13, 2006 for U.S. Appl. No. 09/613,497.
Request for Continued Examination dated Feb. 26, 2007 for U.S. Appl. No. 09/613,497.
Notice of Allowance and Fee(s) Due dated Apr. 5, 2007 for U.S. Appl. No. 09/613,497.
Request for Continued Examination dated Jul. 9, 2007 for U.S. Appl. No. 09/613,497.
Response filed Jul. 19, 2007 for U.S. Appl. No. 09/613,497.
Notice of Allowance and Fee(s) Due dated Aug. 6, 2007 for U.S. Appl. No. 09/613,497.
Non-Final Office Action dated Oct. 18, 2007 for U.S. Appl. No. 11/713,485.
Response filed Mar. 18, 2008 for U.S. Appl. No. 11/713,485.
Non-Final Office Action dated Jun. 26, 2008 for U.S. Appl. No. 11/713,485.
Response filed Sep. 8, 2008 for U.S. Appl. No. 11/713,485.
Non-Final office action Dec. 10, 2008 for U.S. Appl. No. 11/713,485.
Response filed Mar. 4, 2009 for U.S. Appl. No. 11/713,485.
Final Office Action date mailed May 19, 2009 for U.S. Appl. No. 11/713,485.
Interview Summary date mailed Jul. 17, 2009 for U.S. Appl. No. 11/713,485.
RCE/Response filed Aug. 21, 2009 for U.S. Appl. No. 11/713,485.
Notice of Allowance date mailed Nov. 30, 2009 for U.S. Appl. No. 11/713,485.
Restriction Requirement date mailed Nov. 22, 2011 for U.S. Appl. No. 12/711,182.
Response filed Dec. 16, 2011 for U.S. Appl. No. 12/711,182.
Non-final Office Action date mailed May 19, 2009 for U.S. Appl. No. 11/545,321.
Response filed Nov. 19, 2009 for U.S. Appl. No. 11/545,321.
Final Action date mailed Mar. 4, 2010 for U.S. Appl. No. 11/545,321.
Response filed May 4, 2010 for U.S. Appl. No. 11/545,321.
Notice of Allowance date mailed Jun. 11, 2010 for U.S. Appl. No. 11/545,321.
RCE/Response filed Sep. 3, 2010 for U.S. Appl. No. 11/545,321.
Notice of Allowance date mailed Nov. 24, 2010 for U.S. Appl. No. 11/545,321.
Non-Final Office Action dated Jun. 12, 2008 for U.S. Appl. No. 11/702,822.
Response filed Jul. 14, 2008 for U.S. Appl. No. 11/702,822.
Non-Final Office Action dated Aug. 26, 2008 for U.S. Appl. No. 11/702,822.
Response filed Nov. 13, 2008 for U.S. Appl. No. 11/702,822.
Notice of Allowance dated Apr. 16, 2009 for U.S. Appl. No. 11/702,822.
RCE filed Jun. 4, 2009 for U.S. Appl. No. 11/702,822.
Notice of Allowance date mailed Aug. 24, 2009 for U.S. Appl. No. 11/702,822.
Notice of Allowance date mailed Sep. 14, 2009 for U.S. Appl. No. 11/702,822.
Notice of Allowance date mailed Dec. 3, 2009 for U.S. Appl. No. 11/702,822.
Restriction Requirement date mailed Dec. 15, 2011 for U.S. Appl. No. 12/650,318.
Restriction Requirement date mailed Sep. 27, 2010 for U.S. Appl. No. 12/118,524.
Response filed Oct. 20, 2010 for U.S. Appl. No. 12/118,524.
Non-Final Office Action date mailed Jan. 5, 2011 for U.S. Appl. No. 12/118,524.
Interview Summary date mailed Feb. 17, 2011 for U.S. Appl. No. 12/118,524.
Response filed Apr. 5, 2011 for U.S. Appl. No. 12/118,524.
Interview Summary date mailed May 20, 2011 for U.S. Appl. No. 12/118,524.
Notice of Allowance date mailed Jul. 11, 2011 for U.S. Appl. No. 12/118,524.
Related Publications (1)
Number Date Country
20120053539 A1 Mar 2012 US
Provisional Applications (1)
Number Date Country
60928644 May 2007 US
Continuations (1)
Number Date Country
Parent 12118524 May 2008 US
Child 13289827 US